Royalty Report: Drugs, Biotechnology, Cancer – Collection: 7481


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Biotechnology
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7481

License Grant
Licensor hereby grants to Licensee a worldwide exclusive royalty bearing license in the Field to the non-exclusive rights held by Licensor with respect to the TGF-B Antibody Patent Rights to (i) use the TGF-B Antibody Know How, and (ii) to make, have made, use, offer to sell, sell or import into the United States Licensed Product(s) or use Licensed Method(s) in the Territory in which the TGF-B Antibody Patent Rights are effective until the end of the full term(s) for which these Patent Rights are issued, unless sooner terminated as hereinafter provided.
License Property
Licensor is a biopharmaceutical company that is the owner of a certain patent and patent applications and know how relating to monoclonal antibodies that bind Transforming Growth Factor B ('TGF-B'), specifically TGF-B1 and TGF-B2.

Biological Property shall mean any DNA materials, derivatives of such DNA materials, cell lines and peptides containing the DNA materials or derivatives thereof, that are related to the TGF-B Antibody Patent Rights, and to the TGF-B Receptor Patent Rights, respectively.

TGF-B Antibody Patent Rights shall mean the Patent Rights that relate to monoclonal antibodies that bind Transforming Growth Factor ('TGF-B'), specifically TGF-B1 and TGF-B2.

TGF-B Receptor Patent Rights Licensed from MIT shall mean the Patent Rights that relate to TGF-B receptors, including TGF-B type II and TGF-B type III receptors, cDNA of the respective receptors, and methods of use.

Field of Use
Field shall mean uses for any and all purposes with the following exceptions: (i) opthamology, (ii) the TGF-B Antibody Rights previously licensed to Genentech, Inc., and (iii) with respect to the TGF-B Receptor Patent Rights Licensed from MIT only, those rights previously exclusively sublicensed by CELTRIX to R&D Systems.

IPSCIO Record ID: 4451

License Grant
Licensor hereby grants to Licensee an exclusive right and license (including the right to grant sublicenses) in the Territory to make, have made use and sell any Product in the Field (a) the use, manufacture or sale of which is covered by one or more claims of the Patents or (b) incorporating or manufactured using Licensed Technology.
License Property
'Product' means any pharmaceutical composition in the Field incorporating TGF-B and further including appropriate delivery vehicles including without limitation heparin and collagen.

'Initial Indications' means the indications for wound repair and multiple sclerosis; 'Initial Products' shall mean Products for the Initial indications.

'TGF-B' means any and all transforming growth factor Betas (1,2,3,etc) and any fragments, analogs, derivatives or modifications thereof which provides essentially the same biological function as transforming growth factor Betas, including all uses of the foregoing owned, licensed and/or developed by Licensor

'TGF-B2' means transforming growth factor Beta 2 as described in U.S. Patent # 4,774,322.

Field of Use
'Field' means any therapeutic uses of TGF-B for any clinical indication excluding soft tissue augmentation previously licensed, vascular prostheses including stents and grafts previously licensed and all ophthalmic and mucositis indications and uses.

IPSCIO Record ID: 29291

License Grant
The Licensor granted a limited, nontransferable, worldwide patent license, without the right to sublicense, to use the Antibodies solely for the purpose of making and selling the Licensee's Products only in the Research Market.
License Property
Licensor owns and controls certain organisms (cell lines) used in the production of monoclonal antibodies. Monoclonal Antibodies to Human Interferongamma; Monoclonal Antibodies to Human Granulocyte Macrophage-Colony Stimulating Factor; Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha.
Field of Use
Licensee wishes to sell products containing the Monoclonal Antibodies for research use only.

IPSCIO Record ID: 26674

License Grant
The University grants to the Company, (i) an exclusive license under the licensed Patents to develop, manufacture, have made, import, use, sell, have sold, distribute, rent or lease Licensed Products/Services throughout the Territory, together with a right to grand sublicenses.
License Property
Certain patent applications titled Nucleic Acids and Proteins of Insect or 83b odorant receptor genes and uses thereof.” The olfaction intellectual property assets are also referred to herein as “our olfaction intellectual property.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.